<DOC>
	<DOCNO>NCT00491998</DOCNO>
	<brief_summary>The purpose study determine pharmacokinetic profile V1512 similar well exist medication treatment Parkinson 's Disease</brief_summary>
	<brief_title>PK , PD Safety Multiple Doses V1512 Tablets PD Patients Compared Standard Levodopa/Carbidopa Oral Tablets</brief_title>
	<detailed_description>The pharmacokinetics V1512 effervescent tablet evaluate healthy volunteer , however fully PD patient . This study aim evaluate PK profile PD patient different dose schedule V1512 effervescent tablet compare profile standard L-dopa/carbidopa ( Sinemet ) course day . Two dose schedule choose evaluate possible relation dose interval 'ON ' time , without associate dyskinesia . Similar dose schedule comparator Sinemet commonly employ treatment fluctuate PD patient . Patients assign cohort 3 also take dose entacapone concomitantly dose V1512 Sinemet , thereby allow kinetics dynamic of.V1512 Sinemet compare presence COMT inhibition . Safety tolerability dose regimen patient also assess double-blind study</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Entacapone</mesh_term>
	<criteria>1 . Male female , &gt; 30 year age race ; 2 . A Body Mass Index 18.5 29.9 kg/m2 ( inclusive ) ; 3 . Clinical diagnosis accord Brain Bank diagnostic criterion idiopathic Parkinson 's Disease ( 2 3 cardinal symptom bradykinesia , rigidity , tremor must present , positive response Ldopa ) ; 4 . Presence fluctuation motor performance &gt; 2 hour inclusive daytime OFF episode ( applicable cohort 1 patient ) ; 5 . At least 1 hour delay ON time afternoon dos ; 6 . Discontinued use COMT inhibitor ( cathecolomethyl transferase ) least 2 week prior study entry ( applicable cohort 3 patient ) ; 7 . Stable dos dopamine agonist selegiline least 2 week entry study ; 8 . Stable comorbidity 4 week ; 9 . Female patient must nonchildbearing potential ( postmenopausal physically incapable childbearing ) ; 10 . Willing able give inform consent accord national legal requirement prior initiation studyrelated procedure 1 . Clinically relevant abnormal vital sign value safety laboratory data . 2 . Patients smoke unable refrain smoking inclinic period 3 . Diagnosis atypical parkinsonism ; 4 . A history and/or presence gastrointestinal disorder ( surgery ) could interfere absorption test medication ; 5 . A history intolerance clinically relevant allergy Ldopa and/or carbidopa take formulation combination ; 6 . A history intolerance clinically relevant allergy entacapone ingredient Comtan ( cohort 3 patient ) 7 . Any condition , opinion Investigator , would interfere optimal participation study e.g . inability complete patient diary ; 8 . Participation clinical study receive treatment another investigational drug within 30 day 5 half life ( whichever longer ) screen visit ; 9 . Blood donation within 3 month study participation ; 10 . History neuroleptic malignant syndrome ( NMS ) NMSlike syndrome , nontraumatic rhabdomyolysis ; 11 . Patients take nonselective MAO inhibitor ; 12 . Patients history , clinical indication , narrow angle glaucoma ; 13 . Patients history , clinical indication , malignant melanoma ; 14 . Patients history , clinical indication , depression psychosis ; 15 . Patients take iron contain medication ( ferrous sulphate , ferrous gluconate )</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2011</verification_date>
</DOC>